Option Care Health/$OPCH
1D1W1M3M6MYTD1Y5YMAX
Capital at risk
About Option Care Health
Option Care Health Inc is the provider of home and alternate-site infusion services. It provides treatment for bleeding disorders, neurological disorders, heart failure, anti-infectives, and chronic inflammatory disorders, among others. The Company operates in one segment, infusion services.
- Ticker
- $OPCH
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 7,397
- Headquarters
- Bannockburn, United States
- Website
- optioncarehealth.com
OPCH Metrics
BasicAdvanced
$4.7B
23.49
$1.32
0.61
-
Price and volume
Market cap
$4.7B
Beta
0.61
52-week high
$36.80
52-week low
$18.01
Average daily volume
4.9M
Financial strength
Current ratio
1.465
Quick ratio
0.91
Long term debt to equity
0.914
Total debt to equity
1.006
Interest coverage (TTM)
6.41%
Profitability
EBITDA (TTM)
397.159
Gross margin (TTM)
19.06%
Net profit margin (TTM)
3.68%
Operating margin (TTM)
5.72%
Effective tax rate (TTM)
26.59%
Revenue per employee (TTM)
$770,000
Management effectiveness
Return on assets (TTM)
6.02%
Return on equity (TTM)
16.00%
Valuation
Price to earnings (TTM)
23.49
Price to revenue (TTM)
0.858
Price to book
3.69
Price to tangible book (TTM)
-7.3
Price to free cash flow (TTM)
16.084
Free cash flow yield (TTM)
6.22%
Free cash flow per share (TTM)
1.93
Growth
Revenue change (TTM)
5.95%
Earnings per share change (TTM)
4.69%
3-year revenue growth (CAGR)
11.27%
3-year earnings per share growth (CAGR)
0.09%
What the Analysts think about OPCH
Analyst ratings (Buy, Hold, Sell) for Option Care Health stock.
Analyst projections of the future price of Option Care Health stock.
Bulls say / Bears say
The agreed $32.05-per-share acquisition by McKesson and CD&R gives shareholders a defined transaction value, subject to the deal closing. The buyers’ strategic commitment also signals confidence in Option Care’s national infusion platform. (CD&R)
McKesson says Option Care’s home and clinic network fits its push to make complex specialty therapies available in lower-cost community settings. That partnership could support referrals and expansion as demand for specialty infusions grows. (CD&R, Bloomberg Law)
The underlying business remained profitable and generated $184 million of operating cash in the second quarter. Adjusted EPS rose 9.8% year on year, helped by operating execution and lower expenses. (GlobeNewswire)
Management expects chronic inflammatory disease portfolio changes to reduce 2026 gross profit by about $55 million and revenue growth by roughly six percentage points. The drag reflects patient losses and an unfavourable therapy mix. (The Motley Fool)
Underlying growth is still weak: second-quarter revenue rose just 1.9% year on year, while gross profit declined slightly. Adjusted EBITDA growth was only 3%, leaving little evidence so far of a strong organic reacceleration. (GlobeNewswire)
Data summarised monthly by Lightyear AI. Last updated on 6 Oct 2026.
OPCH Financial Performance
Revenues and expenses
OPCH Earnings Performance
Company profitability
Upcoming events
No upcoming events
OPCH News
AllArticlesVideos
Option Care Health Investor Alert: Kahn Swick & Foti, LLC Investigates Adequacy of Price and Process in Proposed Sale of Option Care Health, Inc. - OPCH
Business Wire19 hours ago
This Option Care Health Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday
Benzinga2 days ago
Option Care Stock Trades Below McKesson's Deal Price — Here's the Spread
Benzinga3 days ago
Funds containing OPCH
AllEURGBPUSD
Fund name | Fund size | $OPCH weighting |
|---|---|---|
iShares Ageing Population€AGED | €822M | 0.41% |
SPDR Russell 2000 US Small Cap€R2US | €4.8B | 0.17% |
SPDR Russell 2000 US Small Cap£R2SC | £4.1B | 0.17% |
SPDR S&P 400 US Mid Cap$SPY4 | $6.3B | 0.14% |
SPDR S&P 400 US Mid Cap£SPX4 | £4.7B | 0.14% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.